Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a NeuroAD System, for the Treatment of Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study

NCT02166827 is registered in ClinicalTrials.gov with Neuronix Ltd as lead sponsor.

NCT NCT02166827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02166827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a NeuroAD System, for the Treatment of Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study
Lead sponsor
Neuronix Ltd
Phase
Not applicable
Overall status
Terminated
Start date
November 30, 2014
Completion date
November 30, 2015
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease